Advancing apoptosis

Ascentage to push forward with apoptosis candidates with $72M B round

A RMB500 million ($72 million) series B round will enable Ascentage Pharma Group Corp. Ltd. to generate clinical proof-of-concept data for two to three cancer candidates in three years.

Future Industry Investment Fund led the round, which closed on Dec. 27.

Read the full 413 word article

User Sign In